QGE031 + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Allergy

Conditions

Allergy

Trial Timeline

Mar 1, 2011 → Aug 1, 2012

NCT ID

NCT01596712

About QGE031 + Placebo

QGE031 + Placebo is a phase 1 stage product being developed by Novartis for Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT01596712. Target conditions include Allergy.

What happened to similar drugs?

4 of 14 similar drugs in Allergy were approved

Approved (4) Terminated (3) Active (7)

❌ligelizumab + PlaceboNovartisPhase 3

✅Placebo + XolairNovartisApproved

❌Ligelizumab 120 mg + Ligelizumab 240 mgNovartisPhase 3

🔄Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3

✅OmalizumabNovartisApproved

✅Omalizumab InjectionRocheApproved

✅Fexofenadine HCISanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01451450	Phase 2	Withdrawn	—	—	Peanut Allergy
NCT02336425	Phase 2	Terminated	Sep 1, 2015	Mar 1, 2016	Asthma
NCT01688882	Phase 2	Terminated	Jan 1, 2013	Mar 1, 2015	Bullous Pemphigoid
NCT01596712	Phase 1	Completed	Mar 1, 2011	Aug 1, 2012	Allergy

Competing Products

20 competing products in Allergy

See all competitors

Product	Company	Stage	Hype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo Intramuscular	Astellas Pharma	Phase 1	29
ASP0892 + Placebo	Astellas Pharma	Phase 1	29
Cetirizine 10mg + Cetirizine 10 mg + Cetirizine 10 mg	Johnson & Johnson	Phase 1	29
Cetirizine + Cetirizine	Johnson & Johnson	Phase 1	29
Acalabrutinib	AstraZeneca	Phase 2	35
Omalizumab	Novartis	Phase 1	29
ligelizumab + Placebo	Novartis	Phase 3	32
remibrutinib + placebo	Novartis	Phase 2	35
Placebo + Xolair	Novartis	Approved	39
QGE031 + Placebo	Novartis	Phase 2	27
Ligelizumab 120 mg + Ligelizumab 240 mg	Novartis	Phase 3	32
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral Immunotherapy	Novartis	Phase 3	40
Omalizumab	Novartis	Approved	43
Omalizumab Injection	Roche	Approved	50
Fluticasone + Fluticason	Roche	Pre-clinical	26
Dupilumab + Placebo matching dupilumab + AR101	Sanofi	Phase 2	35
Fexofenadine HCI	Sanofi	Approved	43
Dupilumab	Sanofi	Phase 2	35
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE	Sanofi	Phase 1	29
Dupilumab	Regeneron Pharmaceuticals	Pre-clinical	26